Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 15,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, visit: https://www.pharmaron.com
PharmaVentures is a specialist healthcare consultancy which delivers practical and cost-effective solutions to clients world-wide in the pharmaceutical, biotechnology, healthcare, finance & related service sectors.. . . . Strategy, Analysis, Evaluation. Expert Reports, Due Diligence, Deal Benchmarking, Structuring & Negotiation, Product Partner Identification
No data available
Founded in the UK in 2002, Pharmidex provides high quality experimental preclinical ADMET/PK data, critical to the progression of drug discovery programmes. We have comprehensive in-house laboratory facilities as well as extensive in-vitro and in-vivo assay options. This enables us to provide tailored studies designed to meet individual project needs. Through extensive knowledge of drug discovery and development, Pharmidex has been able to deliver a high level of customer satisfaction and forge several strategic international alliances, focusing on operations in the following areas: in vitro ADMET, in-vivo Pharmacology, CNS Drug Discovery, Bioanalysis, Metabolite Identification, Bioimaging, and Zebrafish.
PhoreMost™ is focused on bringing more effective and affordable targeted medicines to patients. To achieve this aim, PhoreMost is developing a next-generation phenotypic screening technology that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Based on the company's proprietary Protein Interference (PROTEINi®) technology, PhoreMost has developed SITESEEKER®; a platform that can systematically unmask cryptic druggable sites in the human genome and then link them to useful therapeutic functions in a live-cell context.
Watch our Member Showcase Video https://bit.ly/356qf35
No data available
No data available
With a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical support to life scientists in academic, industrial and government settings.. Promega products are used by life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification.. . Promega holds significant intellectual property rights and licenses in several key areas that form a foundation for its diverse portfolio including:. •
No data available